Argentine NGO objects to antiretroviral patent request

297eb22b8a429acf210e6c71bac35e30An Argentine foundation has asked the National Institute of Industrial Property (INPI) to deny a patent request for an antiretroviral drug by the North American pharmaceutical company Gilead Sciences Inc.

The drug, known by its abbreviation TAF (Tenofovir Alafenamide fumarate), is used to treat about half of the people infected with HIV in Argentina (about 45,000 people), and has been used for more than five years.

It is produced by an Argentine laboratory and if a patent were to be granted, its cost would increase considerably, according to the foundation, a non-governmental organisation (NGO). In Brazil the same request by Gilead was rejected in 2017.

Read the full article in SciDev